1–2 ml EDTA blood or 1–2 µg genomic DNA. Alternative material must be confirmed before collection or shipment.
PREVENTION · PRV03
Thrombosis & Coagulation Prevention
Assesses genes associated with hereditary thrombosis, coagulation-factor deficiencies, platelet disorders, and von Willebrand disease.
Targeted next-generation sequencing of the complete coding sequence and relevant splice regions of the selected genes; this is not a hotspot-only screen.
Clinically classified findings, an explanation of the inherited risk, and recommendations for medical follow-up or preventive discussion.
Confirmed after case and sample review.
CLINICAL VALUE
Where this test is strongest
✓28 genes across thrombosis and bleeding
✓Includes natural anticoagulant pathways
✓Includes coagulation factors and platelet genes
✓Can inform preventive or peri-procedural discussion
LIMITATIONS
What must remain visible
!A predisposition is not a diagnosis and does not predict if or when disease will occur.
!A negative result does not remove all inherited or non-genetic risk; selection and interpretation require medical context.
!F8 intronic inversions are not covered by this module and may require a separate method.
GENE & ANALYTICAL SCOPE
28 published genes
The module includes 28 genes; F8 intronic inversions are outside this scope.
Thrombosis & coagulationPRV03 · 28 published genes+
Complete panel scope (28 genes).
ADAMTS13F10F11F12F13A1F13BF2F5F7F8F9GFI1BGP1BAGP1BBGP6GP9HRGITGA2BITGB3LMAN1MCFD2NBEAL2PROCPROS1SERPINC1SERPIND1SERPINF2VWF
BEFORE ORDERING
Confirm the current laboratory specification.
The official case review and quotation confirm eligibility, accepted material, validated coverage and variant classes, consent, turnaround, price, and report pathway.